RN341
RN341 is a specific type II kinase inhibitor of LRRK2 (IC50: 296 nM) . RN341 inhibits LRRK2 phosphorylation and avoids S935 dephosphorylation by stabilizing the open conformation. RN341 rescues LRRK2-mediated kinesin motility block by preventing microtubule binding. RN341 effectively inhibits LRRK2 wild-type and G2019S mutant at the cellular level. RN341 provides a new direction for Parkinson's disease research[1].
Product Specifications
UNSPSC
12352005
Target
LRRK2
Related Pathways
Autophagy
Field of Research
Neurological Disease
Smiles
O=C(NC1=CC(C(C)(C)C)=NN1C2=CC=C(C)C=C2)NC3=CC(C4=CNC5=NC(SCC)=NC(NC)=C54)=CC=C3
Molecular Formula
C30H34N8OS
Molecular Weight
554.71
References & Citations
[1]Nicolai D. Raig, et al. Type II kinase inhibitors that target Parkinson's disease-associated LRRK2. BioRxiv. 2025 Feb 13. 2024.09.17.613365.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD54 / ICAM-1 (15.2), CF405S conjugate, 0.1mg/mL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF568 conjugate, 0.1mg/mL
CD63 (MX-49.129.5), CF594 conjugate, 0.1mg/mL
CD50 (ICAM-3) (101-1D2), CF568 conjugate, 0.1mg/mL
TAG-72 / CA72.4 (B72.3), CF640R conjugate, 0.1mg/mL
